Pharmacogenomics, Pharmacokinetics and Circulating Proteins as Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review

by Apostolos Papachristos, Gregory B. Sivolapenko
Published 2020-08-01

Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer

by Apostolos Papachristos, Eleni Karatza, Haralabos Kalofonos, Gregory Sivolapenko
Published 2020-05-01

Factors incorporated into future survival estimation among Europeans

by Apostolos Papachristos, Georgia Verropoulou, George B. Ploubidis, Cleon Tsimbos
Published 2020-01-01

<i>VEGF-A</i> and <i>ICAM-1</i> Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer

by Apostolos Papachristos, Polychronis Kemos, Theodora Katsila, Eirini Panoilia, George P. Patrinos, Haralabos Kalofonos, Gregory B. Sivolapenko
Published 2019-11-01